| Author | Vasconcelos, Germana Silva | |
| Author | Fernandes, Maria da Conceição Rodrigues | |
| Author | Matsui, Tamires Cardoso | |
| Author | Luciano, Maria Claudia dos Santos | |
| Author | Costa, Cecilia Leite | |
| Author | Ferraz, Clarissa Perdigão Mello | |
| Author | Dias, Fernando Braga Stehling | |
| Author | Miyajima, Fabio | |
| Author | Araújo, Fernanda Montenegro de Carvalho | |
| Author | Fonseca, Marcela Helena Gambim | |
| Access date | 2024-06-03T16:58:27Z | |
| Available date | 2024-06-03T16:58:27Z | |
| Document date | 2023 | |
| Citation | VASCONCELOS, Germana Silva et al. Persistent SARS-COV-2 infection in vaccinated individual with three doses of COVID-19 vaccine. Vaccine, v. 41, n. 11, p. 1778-1782, Mar. 2023. | |
| ISSN | 0264-410X | |
| URI | https://www.arca.fiocruz.br/handle/icict/64284 | |
| Language | eng | |
| Publisher | Elsevier | |
| Rights | open access | |
| Title | Persistent SARS-COV-2 infection in vaccinated individual with three doses of COVID-19 vaccine | en_US |
| Type | Article | |
| DOI | 10.1016/j.vaccine.2023.02.019 | |
| Abstract | We describe a case of a 24-year-old Brazilian woman previously vaccinated with CoronaVac and a booster dose of Pfizer-BioNTech, with mild-to-moderate COVID-19, with persistent viral shedding. We evaluated viral load, antibody dynamics for SARS-CoV-2 and performed genomic analysis to identify the viral variant. The female remained positive for 40 days following symptom onset (cycle quantification mean: 32.54 ± 2.29). The humoral response was characterized by absence of IgM for the viral spike protein, increased IgG for the viral spike (1800.60 to 19558.60 AU/mL) and for the nucleocapsid (from 0.03 to 8.9 index value) proteins, and high titers of neutralizing antibodies (>488.00 IU/mL). The variant identified was the sublineage BA. 5.1. of Omicron (B.1.1.529). Our results suggest that even though the female produced an antibody response against SARS-CoV-2, the persistent infection can be explained by antibody decline and/or the immune evasion by the Omicron variant, illustrating the need to revaccinate or update vaccines. | |
| Affilliation | Fundação Oswaldo Cruz. Fiocruz Ceará. Eusébio, CE, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Fiocruz Ceará. Eusébio, CE, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Fiocruz Ceará. Eusébio, CE, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Fiocruz Ceará. Eusébio, CE, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Fiocruz Ceará. Eusébio, CE, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Fiocruz Ceará. Eusébio, CE, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Fiocruz Ceará. Eusébio, CE, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Fiocruz Ceará. Eusébio, CE, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Fiocruz Ceará. Eusébio, CE, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Fiocruz Ceará. Eusébio, CE, Brasil. | |
| Subject | Antibody response | |
| Subject | COVID-19 | |
| Subject | Omicron variant | |
| Subject | Persistent infection | |
| Subject | RT-qPCR | |
| Subject | SARS-CoV-2 | |
